Cathie Wood’s Ark Innovation and Genomic ETFs have reached a significant milestone, celebrating 10 years since their inception. Investors are eager to see how the annual returns of these ETFs compare to the S&P 500.
Over the past decade, Ark Innovation and Genomic ETFs have proven to be strong performers, consistently outperforming the broader market index. Despite the volatility in the market, these ETFs have shown resilience and have delivered impressive returns to investors.
In terms of annual returns, Ark Innovation and Genomic ETFs have shown strong performance compared to the S&P 500. Investors who have held these ETFs for the past 10 years have seen significant gains, showcasing the potential for long-term growth and success.
As Cathie Wood’s ETFs continue to gain popularity and attract investors looking for innovative and high-growth opportunities, it will be interesting to see how they continue to perform in the years to come. With a track record of success and a focus on disruptive technologies and genomic advancements, Ark Innovation and Genomic ETFs are poised for continued growth and success in the future.